BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 22772380)

  • 1. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
    Pernas S; Gil-Gil M; de Olza MO; Gumà A; Climent F; Petit A; Pla MJ; García-Tejedor A; López-Ojeda A; Falo C; Fernandez-Otega A; Mesia C; Pérez-Martin FJ; Urruticoechea A; Germà JR
    Breast Cancer Res Treat; 2012 Aug; 134(3):1161-8. PubMed ID: 22772380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
    Dawood S; Gonzalez-Angulo AM; Peintinger F; Broglio K; Symmans WF; Kau SW; Islam R; Hortobagyi GN; Buzdar AU
    Cancer; 2007 Sep; 110(6):1195-200. PubMed ID: 17647266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.
    Nakamura S; Ando M; Masuda N; Aogi K; Ino H; Iwata H; Tokuda Y; Yamamoto N; Kasai H; Takeuchi M; Tsuda H; Akiyama F; Kurosumi M; Fujiwara Y
    Clin Breast Cancer; 2012 Feb; 12(1):49-56. PubMed ID: 22154118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
    Buzdar AU; Ibrahim NK; Francis D; Booser DJ; Thomas ES; Theriault RL; Pusztai L; Green MC; Arun BK; Giordano SH; Cristofanilli M; Frye DK; Smith TL; Hunt KK; Singletary SE; Sahin AA; Ewer MS; Buchholz TA; Berry D; Hortobagyi GN
    J Clin Oncol; 2005 Jun; 23(16):3676-85. PubMed ID: 15738535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.
    Buzdar AU; Suman VJ; Meric-Bernstam F; Leitch AM; Ellis MJ; Boughey JC; Unzeitig G; Royce M; McCall LM; Ewer MS; Hunt KK;
    Lancet Oncol; 2013 Dec; 14(13):1317-25. PubMed ID: 24239210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without trastuzumab as primary systemic therapy in locally advanced breast cancer.
    Shimizu T; Hirano A; Kamimura M; Ogura K; Kim N; Watanabe O; Kinoshita J; Kimura K; Ogawa K; Fujibayashi M
    Anticancer Res; 2010 Nov; 30(11):4665-71. PubMed ID: 21115921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
    Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
    Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
    Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
    Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
    Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
    Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
    Buzdar AU; Valero V; Ibrahim NK; Francis D; Broglio KR; Theriault RL; Pusztai L; Green MC; Singletary SE; Hunt KK; Sahin AA; Esteva F; Symmans WF; Ewer MS; Buchholz TA; Hortobagyi GN
    Clin Cancer Res; 2007 Jan; 13(1):228-33. PubMed ID: 17200359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.